Citadel Advisors’s Century Therapeutics IPSC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$351K Buy
205,100
+92,800
+83% +$190K ﹤0.01% 11033
2026
Q2
$275K Buy
+112,300
New +$257K ﹤0.01% 11323
2025
Q1
– Sell
-1,500
Closed -$1.52K – 15003
2024
Q4
$1.52K Sell
1,500
-8,700
-85% -$11.8K ﹤0.01% 14179
2024
Q3
$17.4K Buy
10,200
+9,900
+3,300% +$19.4K ﹤0.01% 12888
2024
Q2
$765 Hold
300
– – ﹤0.01% 13921
2024
Q1
$1.25K Sell
300
-100
-25% -$423 ﹤0.01% 14154
2023
Q4
$1.33K Sell
400
-1,300
-76% -$2.37K ﹤0.01% 13846
2023
Q3
$3.4K Buy
1,700
+1,600
+1,600% +$4.26K ﹤0.01% 13589
2023
Q2
$316 Sell
100
-2,000
-95% -$6.45K ﹤0.01% 14152
2023
Q1
$7.29K Sell
2,100
-200
-9% -$878 ﹤0.01% 13742
2022
Q4
$11.8K Buy
+2,300
New +$21.7K ﹤0.01% 13553

Other funds holding IPSC

Citadel Advisors's IPSC Position: Q3 2026 in Review

Citadel Advisors reduced its Century Therapeutics (IPSC) stake by 33% in Q3 2026, selling an estimated $85.6K and leaving 84,660 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #12616.

Citadel Advisors first reported a position in IPSC in Q3 2021 and has held it in 18 quarters since. The position peaked at $673K in Q4 2022. 102 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

  • Citadel Advisors held 84,660 shares of Century Therapeutics worth $145K as of Q3 2026.
  • Citadel Advisors sold 41,810 Century Therapeutics shares in Q3 2026, an estimated $85.6K.
  • Century Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #12616 holding.
  • Citadel Advisors first reported a position in Century Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Century Therapeutics position peaked at $673K in Q4 2022.
  • 102 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.